Crossmark

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0615-z

Published Online: 2019-05-16

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ornstein, Moshe C. http://orcid.org/0000-0003-0184-3467
Wood, Laura S.

Hobbs, Brian P.

Allman, Kimberly D.

Martin, Allison

Bevan, Michael

Gilligan, Timothy D.

Garcia, Jorge A.

Rini, Brian I.
Funding

Funding for this research was provided by:

Bristol-Myers Squibb (N/A)
License Information

Text and Data Mining valid from 2019-05-16
More Information

Article History

Received: 11 February 2019

Accepted: 8 May 2019

First Online: 16 May 2019

Ethics approval and consent to participate

: The study protocol and consent were approved by the Cleveland Clinic Institutional Review Board (IRB # 17–586).

: No individual data or images are being published.

: M.O. reports researching funding, consulting fees, and speakers’ bureau honoraria from Bristol-Myers Squibb (BMS). L.S.W. reports speakers’ bureau honoraria from BMS. B.R. reports research funding and consulting fees from BMS.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.